Here is the design of a clinical trial:

Official Title: Lung Ultrasound for Early Detection of Silent and Apparent aspiratioN in Infants and Young CHildren With Cerebral Palsy and Other Developmental Disabilities: a New Fast, Safe, Cost-effective Infant-friendly Imaging Tool to Easily Monitor Feeding , Improve Outcomes and Reduce Morbidities (LUNCH)

Included conditions:
- Cerebral Palsy
- Pediatric Neurological Disorder
- Developmental Disability

Study Armgroups:
- {'label': 'LUS-monitored management (LUS-m)', 'type': 'EXPERIMENTAL', 'description': 'In the first 3 months, participants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 evaluations (T1, T2 and T3), plus baseline (T0). At any time point, they will undergo at least one LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities.', 'interventionNames': ['Diagnostic Test: Lung Ultrasound (LUS)-monitored feeding trial']}
- {'label': 'Standard care management (SC-m)', 'type': 'SHAM_COMPARATOR', 'description': 'Sham protocol with LUS performed at the same timepoints. LUS results in the SC-m group will be available only at the time of data analyses for comparison by investigators. They will not be used for clinical decisions.', 'interventionNames': ['Diagnostic Test: Lung Ultrasound (LUS)-monitored feeding trial']}

Interventions:
- {'type': 'DIAGNOSTIC_TEST', 'name': 'Lung Ultrasound (LUS)-monitored feeding trial', 'description': 'LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.', 'armGroupLabels': ['LUS-monitored management (LUS-m)', 'Standard care management (SC-m)']}

Primary Outcomes:
- {'measure': 'respiratory', 'description': 'respiratory illness rate (including pneumonia, wheezing, chronic cough, and apnoea rate)', 'timeFrame': 'long term (T4, at 6 months)'}
- {'measure': 'respiratory', 'description': 'respiratory illness rate (including pneumonia, wheezing, chronic cough, and apnoea rate)', 'timeFrame': 'short term (T3, at 3 months)'}
- {'measure': 'growth', 'description': 'growth rate', 'timeFrame': 'long term (T4, at 6 months)'}
- {'measure': 'growth', 'description': 'growth rate', 'timeFrame': 'short term (T3, at 3 months)'}
- {'measure': 'invasive diagnostic', 'description': 'VFSS/FEES execution rates', 'timeFrame': 'long term (T4, at 6 months)'}
- {'measure': 'invasive diagnostic', 'description': 'VFSS/FEES execution rates', 'timeFrame': 'short term (T3, at 3 months)'}

Please estimate the sample size based on the assumption: 
alpha = 0.05, power = 80%, attrition rate = 15%
Sample size determination
        The required sample size was calculated according to one of the primary outcome measures, which is the difference in LUS scores at T1 between assignment groups, based on preliminary results (alphaâ=â0.05, power (1-Ã err prob)â=â80%, effect size fâ=â1.6) (unpublished data).
        Estimating a conservative attrition rate of 15%, our sample size will include 150 participants over 30Â months.